Bionomics (ASX:BNO) has announced positive topline results from its Phase 2b ATTUNE trial of BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD).
Bionomics announces positive topline results from clinical trial of BNC210
October 2, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 31 October
October 31, 2025 - - Podcast -
Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retires
October 31, 2025 - - Australian Biotech -
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 - - Australian Biotech -
Firebrick Pharma launches new Nasodine Throat Spray for international markets
October 31, 2025 - - Australian Biotech -
Amplia Therapeutics begins trading on U.S. OTCQB Venture Market
October 31, 2025 - - Australian Biotech -
DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facility
October 31, 2025 - - Latest News -
The continued 'false framing' aims to make us feel guilty for wanting more on health
October 31, 2025 - - Latest News
